Header Logo

Connection

CHING-WEI DAVID TZENG to Adenocarcinoma

Back to Details
This is a "connection" page, showing publications CHING-WEI DAVID TZENG has written about Adenocarcinoma.
CHING-WEI DAVID TZENG
Connection Strength
4.775
Adenocarcinoma
  1. Prognosis Associated With CA19-9 Response Dynamics and Normalization During Neoadjuvant Therapy in Resected Pancreatic Adenocarcinoma. Ann Surg. 2023 03 01; 277(3):484-490.
    View in: PubMed
    Score: 0.233
  2. Prognostic significance of preoperative and postoperative CA 19-9 normalization in pancreatic adenocarcinoma treated with neoadjuvant therapy or surgery first. J Surg Oncol. 2022 Nov; 126(6):1021-1027.
    View in: PubMed
    Score: 0.225
  3. Contemporary Assessment of Need for Palliative Bypass After Aborted Pancreatoduodenectomy Following Neoadjuvant Therapy. J Gastrointest Surg. 2022 02; 26(2):352-359.
    View in: PubMed
    Score: 0.219
  4. AJCC 8th edition pathologic nodal staging of resected pancreatic adenocarcinoma predicts survival regardless of treatment sequencing. Surg Oncol. 2022 Mar; 40:101673.
    View in: PubMed
    Score: 0.217
  5. Perioperative blood transfusions and survival in resected pancreatic adenocarcinoma patients given multimodality therapy. J Surg Oncol. 2021 Dec; 124(8):1381-1389.
    View in: PubMed
    Score: 0.212
  6. ASO Author Reflections: Potential Role of Circulating Biomarkers in Resected Pancreatic Adenocarcinoma. Ann Surg Oncol. 2021 Aug; 28(8):4623-4624.
    View in: PubMed
    Score: 0.204
  7. ASO Author Reflections: Tumor Biology and Safe Surgery Remain Major Determinants of Survival After Resection of Pancreatic Adenocarcinoma. Ann Surg Oncol. 2021 Mar; 28(3):1570-1571.
    View in: PubMed
    Score: 0.199
  8. Benefit of Gemcitabine/Nab-Paclitaxel Rescue of Patients With Borderline Resectable or Locally Advanced Pancreatic Adenocarcinoma After Early Failure of FOLFIRINOX. Pancreas. 2019 07; 48(6):837-843.
    View in: PubMed
    Score: 0.183
  9. Circulating Tumor Cells and Transforming Growth Factor Beta in Resected Pancreatic Adenocarcinoma. J Surg Res. 2019 11; 243:90-99.
    View in: PubMed
    Score: 0.182
  10. Is early-stage pancreatic adenocarcinoma truly early: stage migration on final pathology with surgery-first versus neoadjuvant therapy sequencing. HPB (Oxford). 2019 09; 21(9):1203-1210.
    View in: PubMed
    Score: 0.179
  11. Contemporary analysis of complications associated with biliary stents during neoadjuvant therapy for pancreatic adenocarcinoma. HPB (Oxford). 2019 06; 21(6):662-668.
    View in: PubMed
    Score: 0.176
  12. Validation of American Joint Committee on Cancer eighth staging system for gallbladder cancer and its lymphadenectomy guidelines. J Surg Res. 2018 10; 230:148-154.
    View in: PubMed
    Score: 0.170
  13. Vein resection during pancreaticoduodenectomy for pancreatic adenocarcinoma: Patency rates and outcomes associated with thrombosis. J Surg Oncol. 2018 Jun; 117(8):1648-1654.
    View in: PubMed
    Score: 0.169
  14. Failure to operate on resectable gastric cancer: implications for policy changes and regionalization. J Surg Res. 2017 06 15; 214:229-239.
    View in: PubMed
    Score: 0.157
  15. Defining the optimal timing of adjuvant therapy for resected pancreatic adenocarcinoma: A statewide cancer registry analysis. J Surg Oncol. 2016 Sep; 114(4):451-5.
    View in: PubMed
    Score: 0.148
  16. Should gastric cardia cancers be treated with esophagectomy or total gastrectomy? A comprehensive analysis of 4,996 NSQIP/SEER patients. J Am Coll Surg. 2015 Apr; 220(4):510-20.
    View in: PubMed
    Score: 0.134
  17. Treatment sequencing for resectable pancreatic cancer: influence of early metastases and surgical complications on multimodality therapy completion and survival. J Gastrointest Surg. 2014 Jan; 18(1):16-24; discussion 24-5.
    View in: PubMed
    Score: 0.124
  18. Frequency and intensity of postoperative surveillance after curative treatment of pancreatic cancer: a cost-effectiveness analysis. Ann Surg Oncol. 2013 Jul; 20(7):2197-203.
    View in: PubMed
    Score: 0.118
  19. Morbidity of staged proctectomy after hepatectomy for colorectal cancer: a matched case-control analysis. Ann Surg Oncol. 2013 Feb; 20(2):482-90.
    View in: PubMed
    Score: 0.114
  20. Yield of clinical and radiographic surveillance in patients with resected pancreatic adenocarcinoma following multimodal therapy. HPB (Oxford). 2012 Jun; 14(6):365-72.
    View in: PubMed
    Score: 0.110
  21. Chromosomal imbalances in lung adenocarcinomas with or without mutations in the epidermal growth factor receptor gene. Respirology. 2010 May; 15(4):700-5.
    View in: PubMed
    Score: 0.096
  22. Epidermal growth factor receptor (EGFR) is highly conserved in pancreatic cancer. Surgery. 2007 Apr; 141(4):464-9.
    View in: PubMed
    Score: 0.077
  23. ASO Author Reflections: The Value of Serum CEA for Prognostication at Staging and Response Evaluation in Patients with Localized Pancreatic Adenocarcinoma and Nonelevated CA19-9. Ann Surg Oncol. 2024 03; 31(3):1842-1843.
    View in: PubMed
    Score: 0.063
  24. Serum CEA as a Prognostic Marker for Overall Survival in Patients with Localized Pancreatic Adenocarcinoma and Non-Elevated CA19-9 Levels Treated with FOLFIRINOX as Initial Treatment: A TAPS Consortium Study. Ann Surg Oncol. 2024 Mar; 31(3):1919-1932.
    View in: PubMed
    Score: 0.063
  25. Stereotactic body radiotherapy with or without selective dismutase mimetic in pancreatic adenocarcinoma: an adaptive, randomised, double-blind, placebo-controlled, phase 1b/2 trial. Lancet Oncol. 2023 12; 24(12):1387-1398.
    View in: PubMed
    Score: 0.062
  26. Elevated CA 19-9 is associated with worse survival in patients with resected ampullary adenocarcinoma. Surg Oncol. 2023 Dec; 51:101994.
    View in: PubMed
    Score: 0.061
  27. Impact of Adherence to Operative Standards and Stage-Specific Guideline-Recommended Therapy in Nonmetastatic Pancreatic Adenocarcinoma. Ann Surg Oncol. 2023 Oct; 30(11):6662-6670.
    View in: PubMed
    Score: 0.060
  28. Surgical Eligibility Does Not Imply Surgical Equity: Recommendations for Curative Treatment in Patients With Stage I/II Pancreatic Head Adenocarcinoma Differ by Age and Race. Ann Surg. 2023 02 01; 277(2):321-328.
    View in: PubMed
    Score: 0.059
  29. Neoadjuvant Radiotherapy After (m)FOLFIRINOX for Borderline Resectable Pancreatic Adenocarcinoma: A TAPS Consortium Study. J Natl Compr Canc Netw. 2022 07; 20(7):783-791.e1.
    View in: PubMed
    Score: 0.056
  30. FOLFIRINOX as Initial Treatment for Localized Pancreatic Adenocarcinoma: A Retrospective Analysis by the Trans-Atlantic Pancreatic Surgery Consortium. J Natl Cancer Inst. 2022 05 09; 114(5):695-703.
    View in: PubMed
    Score: 0.056
  31. Association of Medicaid Expansion with Pancreatic Cancer Treatment and Outcomes: Evidence from the National Cancer Database. Ann Surg Oncol. 2022 Jan; 29(1):342-351.
    View in: PubMed
    Score: 0.053
  32. Natural history and prognostic factors for localised small bowel adenocarcinoma. ESMO Open. 2020 11; 5(6):e000960.
    View in: PubMed
    Score: 0.050
  33. Postoperative Chemotherapy Benefits Patients Who Received Preoperative Therapy and Pancreatectomy for Pancreatic Adenocarcinoma. Ann Surg. 2020 06; 271(6):996-1002.
    View in: PubMed
    Score: 0.049
  34. Significance of Cancer Cells at the Vein Edge in Patients with Pancreatic Adenocarcinoma Following Pancreatectomy with Vein Resection. J Gastrointest Surg. 2020 02; 24(2):368-379.
    View in: PubMed
    Score: 0.045
  35. Pancreaticoduodenectomy with Mesocaval Shunt for Locally Advanced Pancreatic Adenocarcinoma. Ann Surg Oncol. 2019 Feb; 26(2):652.
    View in: PubMed
    Score: 0.044
  36. Preoperative Therapy for Gastric Adenocarcinoma is Protective for Poor Oncologic Outcomes in Patients with Complications After Gastrectomy. Ann Surg Oncol. 2018 Sep; 25(9):2720-2730.
    View in: PubMed
    Score: 0.043
  37. Neoadjuvant Nab-paclitaxel and Gemcitabine in Borderline Resectable or Locally Advanced Unresectable Pancreatic Adenocarcinoma in Patients Who Are Ineligible for FOLFIRINOX. Anticancer Res. 2018 Jul; 38(7):4035-4039.
    View in: PubMed
    Score: 0.043
  38. Pathologic Response to Preoperative Therapy as a Novel Prognosticator for Ampullary and Duodenal Adenocarcinoma. Ann Surg Oncol. 2017 Dec; 24(13):3954-3963.
    View in: PubMed
    Score: 0.041
  39. Full dose neoadjuvant FOLFIRINOX is associated with prolonged survival in patients with locally advanced pancreatic adenocarcinoma. Pancreatology. 2015 Nov-Dec; 15(6):667-73.
    View in: PubMed
    Score: 0.035
  40. The Addition of Postoperative Chemotherapy is Associated with Improved Survival in Patients with Pancreatic Cancer Treated with Preoperative Therapy. Ann Surg Oncol. 2015 Dec; 22 Suppl 3:S1221-8.
    View in: PubMed
    Score: 0.035
  41. Impact of early disease progression and surgical complications on adjuvant chemotherapy completion rates and survival in patients undergoing the surgery first approach for resectable pancreatic ductal adenocarcinoma - A population-based cohort study. Acta Oncol. 2016; 55(3):265-77.
    View in: PubMed
    Score: 0.035
  42. Treatment of borderline resectable pancreatic cancer. Curr Treat Options Oncol. 2013 Sep; 14(3):293-310.
    View in: PubMed
    Score: 0.031
  43. The cost-effectiveness of neoadjuvant chemoradiation is superior to a surgery-first approach in the treatment of pancreatic head adenocarcinoma. Ann Surg Oncol. 2013 Dec; 20 Suppl 3:S500-8.
    View in: PubMed
    Score: 0.029
  44. Defined clinical classifications are associated with outcome of patients with anatomically resectable pancreatic adenocarcinoma treated with neoadjuvant therapy. Ann Surg Oncol. 2012 Jun; 19(6):2045-53.
    View in: PubMed
    Score: 0.027
  45. EGFR nuclear import in gallbladder carcinoma: nuclear phosphorylated EGFR upregulates iNOS expression and confers independent prognostic impact. Ann Surg Oncol. 2012 Feb; 19(2):443-54.
    View in: PubMed
    Score: 0.026
  46. ErbB3 expression promotes tumorigenesis in pancreatic adenocarcinoma. Cancer Biol Ther. 2010 Sep 15; 10(6):555-63.
    View in: PubMed
    Score: 0.025
  47. Epidermal growth factor receptor (EGFR) intron 1 polymorphism and clinical outcome in pancreatic adenocarcinoma. Am J Surg. 2010 Sep; 200(3):398-405.
    View in: PubMed
    Score: 0.024
  48. The Sequential Radiographic Effects of Preoperative Chemotherapy and (Chemo)Radiation on Tumor Anatomy in Patients with Localized Pancreatic Cancer. Ann Surg Oncol. 2020 Oct; 27(10):3939-3947.
    View in: PubMed
    Score: 0.012
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.